ZYMERGEN INC (ZY) Stock Fundamental Analysis

NASDAQ:ZY • US98985X1000

2.43 USD
+0.04 (+1.67%)
Last: Oct 18, 2022, 08:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZY. ZY was compared to 83 industry peers in the Chemicals industry. While ZY seems to be doing ok healthwise, there are quite some concerns on its profitability. ZY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ZY had negative earnings in the past year.
  • In the past year ZY has reported a negative cash flow from operations.
ZY Yearly Net Income VS EBIT VS OCF VS FCFZY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -77.49%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZY Yearly ROA, ROE, ROICZY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -50 -100 -150 -200

1.3 Margins

Industry RankSector Rank
OM -1836.72%
PM (TTM) -2508.94%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZY Yearly Profit, Operating, Gross MarginsZY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ZY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ZY has more shares outstanding
  • Compared to 1 year ago, ZY has an improved debt to assets ratio.
ZY Yearly Shares OutstandingZY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 20M 40M 60M 80M 100M
ZY Yearly Total Debt VS Total AssetsZY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -4.65, we must say that ZY is in the distress zone and has some risk of bankruptcy.
  • There is no outstanding debt for ZY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACC12.14%
ZY Yearly LT Debt VS Equity VS FCFZY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 200M -200M 400M

2.3 Liquidity

  • ZY has a Current Ratio of 4.59. This indicates that ZY is financially healthy and has no problem in meeting its short term obligations.
  • ZY has a Quick Ratio of 4.47. This indicates that ZY is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.47
ZY Yearly Current Assets VS Current LiabilitesZY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.02% over the past year.
  • The Revenue for ZY has decreased by -22.23% in the past year. This is quite bad
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.08%
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.01%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.49% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 36.42% on average over the next years. This is a very strong growth
EPS Next Y33.88%
EPS Next 2Y20.08%
EPS Next 3Y20.85%
EPS Next 5Y9.49%
Revenue Next Year-21.93%
Revenue Next 2Y16.02%
Revenue Next 3Y24.75%
Revenue Next 5Y36.42%

3.3 Evolution

ZY Yearly Revenue VS EstimatesZY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
ZY Yearly EPS VS EstimatesZY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ZY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ZY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZY Price Earnings VS Forward Price EarningsZY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.16
ZY Per share dataZY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

  • ZY's earnings are expected to grow with 20.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.08%
EPS Next 3Y20.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ZY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYMERGEN INC

NASDAQ:ZY (10/18/2022, 8:22:57 PM)

2.43

+0.04 (+1.67%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-15
Earnings (Next)11-11
Inst Owners5.74%
Inst Owner Change0%
Ins Owners6.26%
Ins Owner Change0%
Market Cap253.58M
Revenue(TTM)14.55M
Net Income(TTM)-364.95M
Analysts43.64
Price Target2.35 (-3.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.26%
Min EPS beat(2)-48.26%
Max EPS beat(2)3.74%
EPS beat(4)1
Avg EPS beat(4)-13.75%
Min EPS beat(4)-48.26%
Max EPS beat(4)3.74%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.54%
Min Revenue beat(2)-20.33%
Max Revenue beat(2)29.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.44%
Min Revenue beat(4)-20.33%
Max Revenue beat(4)29.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.43
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.1
EV/EBITDA -0.16
EPS(TTM)-3.34
EYN/A
EPS(NY)-2.53
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0.14
BVpS2.27
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1836.72%
PM (TTM) -2508.94%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 4.47
Altman-Z -4.65
F-Score4
WACC12.14%
ROIC/WACCN/A
Cap/Depr(3y)134.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.08%
EPS Next Y33.88%
EPS Next 2Y20.08%
EPS Next 3Y20.85%
EPS Next 5Y9.49%
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.01%
Revenue Next Year-21.93%
Revenue Next 2Y16.02%
Revenue Next 3Y24.75%
Revenue Next 5Y36.42%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.51%
OCF growth 3YN/A
OCF growth 5YN/A

ZYMERGEN INC / ZY FAQ

What is the fundamental rating for ZY stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZY.


What is the valuation status for ZY stock?

ChartMill assigns a valuation rating of 2 / 10 to ZYMERGEN INC (ZY). This can be considered as Overvalued.


Can you provide the profitability details for ZYMERGEN INC?

ZYMERGEN INC (ZY) has a profitability rating of 1 / 10.


How financially healthy is ZYMERGEN INC?

The financial health rating of ZYMERGEN INC (ZY) is 6 / 10.